For the year ending 2025-12-31, URGN made $109,788K in revenue. -$153,531K in net income. Net profit margin of -139.84%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 109,788 | 90,398 | ||
| Cost of revenue | 12,447 | 8,881 | ||
| Gross profit | 97,341 | 81,517 | ||
| Research and development expenses | 67,107 | 57,145 | ||
| Selling, general and administrative expenses | 155,097 | 121,154 | ||
| Operating loss | -124,863 | -96,782 | ||
| Financing on prepaid forward obligation | 18,503 | 23,411 | ||
| Interest expense on long-term debt | 15,345 | 12,521 | ||
| Interest and other income, net | 5,295 | 8,672 | ||
| Loss before income taxes | -153,416 | -124,042 | ||
| Income tax expense | 78 | 2,832 | ||
| Net loss | -153,494 | -126,874 | ||
| Unrealized income (loss) on investments | -37 | 44 | ||
| Comprehensive loss | -153,531 | -126,830 | ||
| Basic EPS | -3.19 | -2.96 | ||
| Basic Average Shares | 48,116,098 | 42,876,737 | ||
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)